| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Smith Robert Paul JR | Chief Commercial Officer | 3115 MERRYFIELD ROW, SUITE 120, SAN DIEGO | /s/ Jeff Boerneke, Attorney-in-Fact | 02 Oct 2025 | 0002003059 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | GOSS | Common Stock | Award | $0 | +163K | $0.00 | 163K | 01 Oct 2025 | Direct | F1 | |
| holding | GOSS | Common Stock | 25K | 01 Oct 2025 | By family trust |
| Id | Content |
|---|---|
| F1 | Represents performance stock unit award, which will vest in full upon the earlier of (i) the approval of a new drug application for seralutinib or (ii) a change in control, in either case on or prior to the fourth anniversary of the grant date, and subject to the Reporting Person's continuous service to the Issuer. |